RxDoctor Payments Data

Frank Valeri, MD

Cardiovascular Disease · Charlotte, NCNPI 1124061569

Payments from drug & device makers

$816in general payments, 2019–2025

Across 46 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$358
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$287
  • Edwards Lifesciences$71
  • Kestra Medical Technology Services, Inc.$33
  • E.r. Squibb & Sons, L.L.C.$31
  • Pfizer$21
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$816 in reported general payments places this provider in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,023
Medicare patients
481
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$205,936
EntrestoSacubitril/Valsartan30$32,278
XareltoRivaroxaban27$28,691
Repatha SureclickEvolocumab14$15,921
Metoprolol Succinate186$1,910
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,878
Ranolazine ErRanolazine15$1,496
Atorvastatin Calcium108$925
Carvedilol134$870
ClopidogrelClopidogrel Bisulfate82$740
Amiodarone Hcl11$707
Lisinopril54$526
Hydralazine Hcl46$519
Spironolactone90$472
Tiadylt ErDiltiazem Hcl20$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$205,936161 claims
NovartisEntresto$358$32,27830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →